The Present and Future of Prostate Cancer Urine Biomarkers
Rigau, Marina (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Olivan, M. (Hospital Universitari Vall d'Hebron. Institut de Recerca)
García, Marta (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Sequeiros, Tamara (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Montes, Melania (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Colás Ortega, Eva (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Llauradó i Miravall, Marta (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Planas, Jacques (Hospital Universitari Vall d'Hebron. Institut de Recerca)
de Torres, Inés (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques)
Morote Robles, Juan (Universitat Autònoma de Barcelona. Departament de Cirurgia)
Cooper, Colin (Cancer Genetics, University of East Anglia, Norwich Norfolk, NR4 7TJ, UK; E-Mails: (C.C.); (J.C.))
Reventós, Jaume (Universitat Internacional de Catalunya. Departament de Ciències Bàsiques)
Clark, Jeremy (Cancer Genetics, University of East Anglia, Norwich Norfolk, NR4 7TJ, UK; E-Mails: (C.C.); (J.C.))
Doll, Andreas (Hospital Universitari Vall d'Hebron. Institut de Recerca)

Date:	2013
Abstract:	In order to successfully cure patients with prostate cancer (PCa), it is important to detect the disease at an early stage. The existing clinical biomarkers for PCa are not ideal, since they cannot specifically differentiate between those patients who should be treated immediately and those who should avoid over-treatment. Current screening techniques lack specificity, and a decisive diagnosis of PCa is based on prostate biopsy. Although PCa screening is widely utilized nowadays, two thirds of the biopsies performed are still unnecessary. Thus the discovery of non-invasive PCa biomarkers remains urgent. In recent years, the utilization of urine has emerged as an attractive option for the non-invasive detection of PCa. Moreover, a great improvement in high-throughput "omic" techniques has presented considerable opportunities for the identification of new biomarkers. Herein, we will review the most significant urine biomarkers described in recent years, as well as some future prospects in that field.
Grants:	Instituto de Salud Carlos III PI11-02486 Instituto de Salud Carlos III CP10-00355 Instituto de Salud Carlos III PS09-00496 Ministerio de Ciencia e Innovación RTICC RD06-0020-0058 Agència de Gestió d'Ajuts Universitaris i de Recerca SGR00487
Note:	Altres ajuts: Asociación Española Contra el Cáncer Junta Provincial de Barcelona; Red de Genómica del Cáncer y Genotipado de tumores C03/10; Movember Foundation 2012, Valor 2010/00220, programa INNPACTO and Lisa Piccione for reviewing the document.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Prostate cancer ; Biomarker ; Irine ; Non-invasive
Published in:	International journal of molecular sciences, Vol. 14 (june 2013) , p. 12620-12649, ISSN 1422-0067

DOI: 10.3390/ijms140612620
PMID: 23774836

30 p, 2.0 MB

The record appears in these collections:
Articles > Research articles
Articles > Published articles